TS-068425 — Functionalization of scFvs with cyclic peptide linkers

TS-068290 — The Need Radiation exposure poses significant health risks, including cancer and other illnesses, making it crucial for clinicians to accurately measure and assess the extent of radiation exposure. Existing methods often require invasive procedures and may not detect exposure at lower dose ranges. …

TS-066912 — Targeted humanized mAbs and ADCs for cancer treatment

TS-066773 — The Need Cardiomyopathy, a disease of the heart muscle, poses significant public health challenges due to its diverse causes, symptoms, and potential complications, including heart failure and arrhythmias. With cardiomyopathy often induced by drugs, such as anthracyclines used in chemotherapy, ther…

TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.

TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.

TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.

TS-065453 — The Need: Colon cancer remains one of the most prevalent and lethal forms of cancer worldwide. Timely and accurate diagnosis is critical for effective treatment and improved patient outcomes. Current diagnostic methods often lack the precision and sensitivity needed for early detection and prognosi…

TS-064577 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately only 40% living past the first-year post-diagnosis and 17% in the second year. The Need Developing drugs for cance…

TS-064262 — The Need Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…

TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…

TS-062715 — Radiopaque biodegradable polymer for the tracking of the breast tissue tumor cavity after lumpectomy and other radiation therapy applications

TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.

TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…

TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…

TS-062681 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…

TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…

TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…

TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…

TS-062605 — The Need: Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…

TS-062548 — The Need: Enhancing Surgical Precision with Anti-TAG-72 Imaging Agents Colorectal carcinoma is a significant medical challenge, with a high incidence rate in the USA. Current surgical approaches, along with external imaging technologies, have limitations in accurately detecting cancerous tissues, l…

TS-062480 — Novel therapeutic compounds to treat advanced liposarcoma.

TS-062384 — , T2018-092, T2018-354, & T2020-216 This technology provides novel radiosensitizer compounds that are derivatives of papaverine designed to enhance tumor oxygenization without PDE-related side effects.

TS-062322 — The Need The field of molecular biology faces a critical commercial need in the effective diagnosis, treatment, and prevention of cancer-related disorders associated with mismatch repair (MMR) dysfunction. Diseases such as Lynch Syndrome (LS) and hereditary non-polyposis colorectal cancer (HNPCC), …

TS-062318 — The Need Cancer is a significant health problem and a leading cause of death in developed countries. Solid cancers, including prostate, breast, lung, stomach, colon, and pancreatic cancers, pose particularly challenging diagnostic and treatment obstacles. Early detection of these cancers is crucial…

TS-062306 — The Need Ovarian cancer is a significant health concern, being the leading cause of gynecological cancer-related deaths in the developed world. Current treatments, such as platinum-based chemotherapy, have limited success due to issues like late-stage diagnosis and chemoresistance. Identifying mole…

TS-062305 — The Need: Colorectal cancer (CRC) is a significant health concern, with a high incidence rate and limited treatment options, particularly regarding resistance to standard chemotherapy like 5-fluorouracil (5-FU). The management of CRC patients is complicated by the frequent occurrence of primary or a…

TS-062303 — The Need: Cancer continues to be a significant global health challenge, with conditions like non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) often diagnosed at advanced stages, resulting in poor prognoses. Existing treatment methods, such as TRAIL-based therapy, face obstacle…

TS-062299 — The Need: Addressing Prostate Cancer Diagnostics and Therapeutics Prostate cancer remains a significant challenge in medical diagnosis and treatment, requiring advancements in diagnostics, therapeutics, and prognostics. Current approaches fall short in providing accurate and effective solutions, le…

TS-062298 — The Need: Ovarian cancer remains a significant challenge in the field of medicine, with late-stage diagnosis and limited effective treatments contributing to high mortality rates. The need for improved diagnostic tools and targeted therapies is evident to address this aggressive disease. Convention…

TS-062296 — The Need: Advancing Lung Cancer Detection and Treatment Lung cancer continues to be a global health concern, accounting for the highest number of cancer-related deaths worldwide. In the United States, it is the leading cause of cancer mortality for both men and women, with a disheartening five-year…

TS-062295 — The Need: Breast cancer continues to be a significant health challenge, affecting a large number of women worldwide and remaining the second leading cause of cancer-related deaths among women in the United States. Despite advancements in detection and treatment, there is no universally successful m…

TS-057778 — A novel monoclonal antibody (PIIO-1) targeting the ligand-free form of GARP, the non-signaling docking receptor for TGFβ. PIIO-1 distrupts transforming growth factor-β (TGF-β) signalling in the tumor microenvironment, primarily on T regulatory cells, consequently augmenting anti-tumor immunity and overcoming ICB resistance . Unlike market competitors, ABBV-151 and DS-1055a which bind the TGF-β1/GARP complex, PIIO-1 prevents activation of all 3 TGF-β isoforms, avoiding isoform compensation and avoiding the potential on-target, adverse effects of binding the TGF-β1/GARP complex found on platelets.

TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.

TS-057739 — CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.

TS-055268 — The laboratory of Dr. Rosa Lapalombella in collaboration with Dr. James Blachly at The Ohio State University has developed a mouse model of spontaneous Chronic Lymphocytic Leukemia.

TS-049827 — circPCMTD1 is a novel target in p53 mutated leukemias.

TS-049730 — Dysregulated fat metabolism is an established hallmark of cancer cells. However, the disruption of lipid homeostasis in cancer cells remains an elusive target for therapy. Tumor cells acquire abundant fats for rapid cell growth, but how they avoid toxicity from such loading is unknown. An answer t…

TS-049491 — Dr. Christin Burd's lab at The Ohio State University has developed a set of Nras-mutant mouse melanoma cell lines that can be used for preclinical tumor immunology and cancer biology studies.

TS-047118 — Analogues of verticillin with significantly improved drug-like properties, including increased solubility, absorption, and stability, while maintaining similar anticancer potency as the verticillin parent compounds.

TS-043186 — A novel acoustic/ultrasonic wave-energy guiding system that utilizes structural topology to enhance directional and spectral sensitivities instead of phase delay, offering exceptional versatility and adaptable performance.

TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.

TS-039267 — A non-invasive and automated tumor budding image analysis system for colorectal cancer. This program can detect tumor buds in traditional H&E stained sections without the need for manual assessment.

TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.

TS-038384 — A novel device for monitoring cancer cell motility in real time using standard microscopy.

TS-037968 — The medical physics group in the Department of Radiation Oncology has devised a 6DoF phantom that is the first of its kind to fully integrate multiple routine QA tests specifically for a six degrees-of-freedom linac table.

TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.

TS-037521 — A method to use MiRNA to predict the likelihood of biochemical failure after radiation surgery.

TS-036760 — Immunomodulating agents have been engineered from Notch receptor ligand extracelluar domains. These are useful for stimulating the immune system.

TS-030264 — A chemical process to produce ceratamine A and B.